With age, the trip to -your doctor for the annual physical check-up can be a daunting one. A perfect blood and lipid profile during youth slowly caves in to the inevitable process of aging, leading to slow but steady deflections in physiological metrics. For many, an especially surprising result is that of the levels of low-density lipoprotein cholesterol (LDLc) and the ratio of its comparison to high-density lipoprotein cholesterol (HDLc). LDL and HDL are lipoproteins that bind and transport cholesterol in the body. LDL delivers it to cells and HDL drives cholesterol transport away from cells and into the liver.
While it is known that a sedentary lifestyle and growing obesity are contributing factors to imbalances in lipid profiles, what is surprising is that often the seemingly fit or lean are also susceptible to increases in LDLc. An increase in cholesterol levels in itself is asymptomatic, but long-term risks include a host of cardiovascular complications. In fact, cardiovascular diseases are the world's number one cause of death and a major medical problem in both developed and developing countries. The CDC estimates that more than a third of American adults have high LDL levels and of these, only a third are able to control it in some way. Diet and exercise are of course useful measures; however, patients that are genetically predisposed to hypercholesterolemia or other cardiovascular complications require additional clinical options.
Since the late 80s, drugs known as statins have been at the forefront of cholesterol-reduction efforts. Statins target the enzyme HMG-CoA reductase, which is a key rate-limiting factor in cholesterol synthesis. Various versions of the drug have been shown to not just directly lower LDL levels but also strongly reduce cardiovascular disease-associated complications as well as deaths (Reiner, 2013) . While largely considered to be safe, some patients experience side effects such as myopathy or show limited to no benefit with statin medication (Dadu and Ballantyne, 2014) . Over the last decade, large-scale genetic studies have linked elevated LDL cholesterol levels as a risk factor for the development of cardiovascular disease, identifying specific genes such as LDLR, APOB, and PCSK9 as possibly playing a direct role (Lange et. al, 2014) . PCSK9 was found through genetic studies documenting familial hypercholesterolemia and molecular studies that characterized it as a member of the proprotein convertase family of serine proteases that play a role in a range of metabolic, infectious, and neurodegenerative diseases (Artenstein and Opal, 2011) . In humans, PCSK9 is primarily expressed in the liver, intestine, kidney, and brain, though recent studies have detected its expression in other tissues as well (Artenstein and Opal, 2011) . Secreted PCSK9 binds to the LDL receptor and targets it for lysosomal degradation. With fewer LDL receptors expressed at the cell surface to bind circulating LDL cholesterol, overall LDL levels rise. Loss-of-function mutations in PCSK9 thus result in reduced LDL cholesterol levels and it is therefore not surprising that this protein emerged as a potentially interesting and promising therapeutic target for the control of hypercholesterolemia and its associated complications (Dullaart, 2017) .
In 2008, a study showed that siRNA nanoparticles could be used to knock down PCSK9 in rodent and non-human primate models and that this resulted in a marked reduction in overall LDL cholesterol levels, without affecting HDL or triglycerides (Frank-Kamenetsky et al., 2008) . Earlier this year, a phase 1 trial used a similar approach testing the effect of inclisiran, a lipid nanoparticle containing siRNAs against human PCSK9 (Fitzgerald et al., 2017) . A range of concentrations and dose regiments were tested in a small cohort of 69 patients that all had LDL levels of 100 mg/dL, which is considered just above optimal. Interestingly, patients that received a subcutaneous single dose of 300 mg or more of inclisiran showed almost a 60% reduction in LDL cholesterol for up to 84 days, suggesting that on a practical level, patients would need a dose only every few months (Fitzgerald et al., 2017) . However, what has not been clear in the field is whether lowered LDL cholesterol levels alone are an indicative metric to suggest long-term cardiovascular benefits and how predictive these observed effects in the trials really are to prevent complications such as stroke, atherosclerosis or myocardial infarction.
Humanized antibodies against PCSK9 such as evolocumab and alirocumab have provided the other therapeutic leads in this field (Natarajan and Kathiresan, 2016) . By binding extracellular PCSK9 and preventing its interaction with the LDL receptor, these antibodies have demonstrated up to a 61% reduction in levels in patients (Dullaart, 2017) . However, the question of what this means for longterm cardiovascular protection remained unexplored. Now a trial with nearly 27,000 patients across 49 countries over a 2 year period has helped to address whether subcutaneous evolocumab administration could provide benefits beyond lowering LDL levels. Besides a 59% reduction in LDL levels, the authors noted a decrease in the cumulative incidence of several cardiovascular events including myocardial infraction, stroke, angina, and even death after a 2 year follow up. The authors thus conclude that there are indeed longterm benefits, though whether this therapy is clearly preventive for developing cardiovascular disease remains to be seen (Sabatine et al., 2017) .
In both, the RNAi and antibody therapy studies, the majority of the patients were also taking statins. While not exactly additive, there seems to be some synergy between statins and anti-PCSK9 therapeutics in terms overall benefit. Further, the authors of the recent evolocumab study note that there is a need for more long-term follow up to see what the effects of lower LDLc levels are in terms of cardiovascular disease protection, given that prior trials with statins and other drugs have shown that a longer window is needed to really see the effects on myocardial infarction, stroke, and related death (Sabatine et al., 2017) . Importantly though, little if any complications or major side effects have been observed in the various studies targeting PCSK9 in animal models and humans. Together, these recent studies provide new and exciting therapeutic promise toward tackling the biggest non-infectious source of death worldwide.
